<DOC>
	<DOCNO>NCT00293059</DOCNO>
	<brief_summary>The purpose study determine whether study drug safe effective treatment dysfunctional uterine bleeding .</brief_summary>
	<brief_title>Efficacy Safety Study Treatment Dysfunctional Uterine Bleeding</brief_title>
	<detailed_description>This study previously post Berlex , Inc. Berlex , Inc. rename Bayer HealthCare Pharmaceuticals , Inc.Bayer HealthCare Pharmaceuticals , Inc.is sponsor trial .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Uterine Hemorrhage</mesh_term>
	<mesh_term>Metrorrhagia</mesh_term>
	<mesh_term>Dienogest</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Nandrolone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Women 18 year old With diagnosis dysfunctional uterine bleeding without organic pathology And least one follow symptom : prolong , frequent , excessive bleed The use steroidal oral contraceptive , drug could alter oral contraception metabolism prohibit study . Women history endometrial ablation dilatation curettage within 2 month prior study start exclude .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Dysfunctional Uterine Bleeding</keyword>
</DOC>